Clinical Trial Update: Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating epigallocatechin gallate (EGCG) for Huntington disease has completed (ETON-Study), sponsored by Charité University in Berlin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• EGCG (Epigallocatechin gallate) (Epigallocatechin gallate)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED